Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs

This is the authors' abstract. We don't add key points for this paper.

Angiogenesis is essential for tumor growth and metastasis, yet physiological angiogenesis is equally critical for tissue repair and endothelial homeostasis. This creates a therapeutic dilemma: suppressing tumor neovascularization without impairing vascular integrity in healthy organs, particularly under cytotoxic chemotherapy. This review summarizes key pro- and anti-angiogenic pathways that regulate tumor vascularization, highlights limitations of current anti-angiogenic therapies (including resistance and delivery barriers), and synthesizes evidence that selected phytochemicals exert context-dependent angiogenesis modulation . Specifically, many compounds inhibit pathological tumor angiogenesis (via VEGF/HIF-1α/NF-κB/MMP-related signaling) while supporting endothelial defense and microvascular recovery in non-cancerous tissues through antioxidant, anti-inflammatory, and anti-apoptotic pathways (e.g., Nrf2/HO-1). Finally, we discuss translational requirements—bioavailability, standardization, dosing windows, and safety—to inform rational adjunct development and future biomarker-driven clinical trials.